adenosine deaminase

Antibody responses to bacteriophage X174 in patients with adenosine deaminase deficiency.

Michael S Hirschfield, Duke University Medical Center, North Carolina, for providing test facilities for ADA (adenosine deaminase), PNP (purine nucleoside phosphorylase), dAXP (total deoxyadenosine nucleotide) and %dAXP (dAXP/AXP+dAXP) levels as well as for mutation analysis.

Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).

Combined use of the polymerase chain reaction and detection of adenosine deaminase activity on pleural fluid improves the rate of diagnosis of pleural tuberculosis.

Most DBA patients also have an increase in fetal Hgb, a decrease in adenosine deaminase activity, and reticulocytosis.

Adenosine deaminase (ADA) is a purine catabolic enzyme with the highest concentration of lymphoid tissue in mammalian tissue.

Adenosine deaminase called ADA by Spencer et al [5] is an enzyme of purine catabolism which catalyses the pathway from adenosine to inosine.

Adenosine deaminase (ADA) level in tubercular pleural effusion.

Adenosine deaminase levels (ADA) are used as marker of cell mediated immunity, especially the ADA levels are markers of T-lymphocyte activation.

Objective: To determine diagnostic accuracy of Cerebro Spinal Fluid (CSF) Adenosine DeAminase (ADA) in detecting Tuberculous Meningitis (TBM) keeping CSF Polymerase Chain Reaction (PCR) for Mycobacterium Deoxy Ribonucleic Acid (DNA) as gold standard.

Revcovi is a new enzyme replacement therapy for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.

* Diagnostic aids: clinical aids, aids for the epidemiological link, radiological aids, aids with adenosine deaminase and tuberculin.

A genetic mutation causes a lack in the adenosine deaminase enzyme, which enables immune cells to fight infection.

The portfolio of gene therapy programmes Orchard has acquired includes: Strimvelis, the first autologous ex vivo gene therapy for children with adenosine deaminase severe combined immunodeficiency (ADA-SCID), approved by the EMA in 2016, two late-stage clinical programmes in ongoing registrational studies for metachromatic leukodystrophy (MLD) and Wiskott Aldrich syndrome (WAS), and one clinical programme for beta thalassaemia.